Fekra's Lead Program is FT-01
A first-in-class BMX cytoplasmic tyrosine kinase inhibitor
For Castration-Resistant Prostate Cancer (CRPC)
FT-01's Scientific and IP References
- Chen, S. et al. (2018) BMX-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer. Cancer Res., 78(18), 5203-5215.
- Liu, F. et al. (2013) Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer. ACS Chem. Biol., 8, 7, 1423–1428.
- Patent: PCT/US2013/065689